Princeton to give students unapproved vaccine
PRINCETON, N.J. — Princeton University officials decided Monday to make available a meningitis vaccine that hasn’t been approved in the U.S. to stop the spread of the sometimes deadly disease on campus.
The university said doses of the vaccine for the type B meningococcal bacteria are to be available in December and February for all undergraduate students, graduate students who live in dorms and university employees who have sickle cell disease and other medical conditions that make them more susceptible to meningitis. The university said the plan was recommended by the U.S. Centers for Disease Control and Prevention.
The vaccinations are to be paid for by the university and are not mandatory. Officials say they are most effective in two doses. Since March, seven cases of meningitis have been confirmed on the New Jersey campus with six students and a visitor diagnosed, the most recent last week. None of the cases has been fatal.
Last week, the federal Food and Drug Administration approved importing the vaccine, Bexsero, for possible use at the Ivy League school. Princeton spokesman Martin Mbugua said university officials considered a number of factors before deciding to move ahead with the plan, but he declined to say what those factors were. The vaccine is in the approval process in the U.S.
Bacterial meningitis is a disease that can cause swelling of the membranes covering the brain and spinal cord. It’s fairly rare in the United States, but those who get it develop symptoms quickly and can die in a couple of days. Survivors can suffer mental disabilities, hearing loss and paralysis.